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The recent announcement that WHO
has approved the use of a combination of
nifurtimox and eflornithine to treat chron-
ic Gambian sleeping sickness, caused by
Trypanosoma brucei gambiense, is a welcome
step in the seemingly interminable process
of searching for less toxic drugs to treat
this devastating disease [1]. Arsenical
drugs were first used in 1905; melarsoprol
remains the drug most frequently used for
late stage disease and is a drug for which
resistance is now a major problem [2].
Over the last 50 years the needs of
countries afflicted by sleeping sickness and
of the foci of infection have changed little,
and neither have our priority needs for
research and disease management: cheap
point-of-care diagnostics and effective,
non-toxic, and affordable drugs for late
stage, or stage 2 disease. What is standing
in the way of attaining these apparently
modest research aims? Surprisingly, one
problem is the very nature of the trypano-
some and its vector the tsetse fly; these
beautiful and biologically fascinating crea-
tures continue to attract considerable
research funding, resulting in a burgeon-
ing industry; a PubMed search for Try-
panosoma brucei reveals 2,624 papers pub-
lished in the last decade producing outputs
that, while admittedly elegant, are remote
from the needs of patients from afflicted
rural populations and are disproportionate
to the sums needed to support research to
assist disease management. Could it be
that, as development economists suspect,
‘‘we have here a silent conspiracy of
professional interests whose scientific work
is justified on the basis of poverty reduc-
tion but who would be devastated if they
were actually successful in these terms?’’
[3]. It would be timely now to take a very
hard look at the global research agenda
within the context of a forgotten hinter-
land which, up until the 1960s, demon-
strated that this disease could be controlled
effectively by unsophisticated means—a
history all too conveniently forgotten by,
or perhaps unknown to, most of the
current generation of researchers.
The ability of the medical services to
translate effective tools and technologies
into public health successes when faced
with the devastating epidemics of the past
was dependent on dedicated teams, skilled
staff, and adequate and appropriate fi-
nancing. In West Africa, epidemics of
Gambian sleeping sickness were controlled
by the use of chemoprophylactic treatment
or ‘‘pentamidisation’’ of populations led by
Jamot and military style campaigns; in
East and southern Africa where the
authorities were equally concerned with
the health of livestock, the diagnosis and
treatment approach for Rhodesian sleep-
ing sickness was allied to vector control
[4]. Targeted, effective, and appropriate
research (supported largely by French and
British aid) allied to realistic health service
delivery options worked, and by the 1960s
sleeping sickness was not considered a
significant public health problem. The
numbers of new cases each year was
minimal and controlled effectively in all
endemic countries of West and Central
Africa through active screening by mobile
teams who diagnosed cases by microscopy
(gland puncture and lumbar puncture) and
treated patients with pentamidine or
suramin and melarsoprol as appropriate.
Whilst there were relapses, there was also
regular follow-up and the observed trend
towards increasingly frequent detection of
early disease was a testament to the
effectiveness of the system. For T. b.
gambiense, diagnosis was improved initially
by the use of immunofluorescence tests
and later, the more practical card agglu-
tination test for trypanosomiasis (CATT)
developed in the 1970s. The CATT test is
perhaps the sole relevant product de-
ployed at any scale to emerge from the
huge amount of research resources devot-
ed to trypanosome antigenic variation. Yet
today, the CATT test remains largely
underused, due to the cost of the product
and packaging (in units of 50), working out
at around US$2 per test [5].
The launch of the Drugs for Neglected
Diseases Initiative (DNDi) has focused
attention on the need for new drugs for
sleeping sickness as well as other kineto-
plastid infections (T. cruzi and Leishmania).
The registration of the nifurtimox/eflor-
nithine combination marks progress in
improvement of the treatment option for
patients with T. b. gambiense—albeit at a
snail’s pace, given that van Nieuwenhoeve
did the initial work on eflornithine in 1985
(he also had the vision to suggest the use of
nifurtimox for relapse cases) [6]. Seven-
teen years later, adoption of even a small
improvement in treatment regimes is a
step forward. As the trypanosome bio-
chemist Jim Williamson so cogently re-
marked ‘‘there have been many more
reviews of trypanosome chemotherapy
than new drugs’’ [7]. However, the
challenge of the eflornithine/nifurtimox
option, even if this combination therapy is
available as an ‘‘essential drug,’’ is classic:
transport of a weighty product; the
difficulties of intravenous administration
in rural settings where health facilities are
minimal; drug availability and affordabil-
ity; the intensity of the specialised medical
care required for patients; the monitoring
of side effects and the potential for relapses
requiring regular follow-up: all costly
activities where patients are beyond the
end of the road. WHO has reported a
significant decline in the numbers of new
cases over the last five years, indicating
that sleeping sickness is coming under
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data on sleeping sickness deaths are
subject to gross errors due to under-
reporting [9] as the majority of people
affected are beyond the reach of health
care systems and are not reported in any
of the health metrics [10]. However, any
apparent improvement in incidence is the
result of the deployment of classical
approaches as opposed to any new ad-
vance in therapy. The agreement by
Sanofi-Aventis and Bayer to donate the
necessary drugs to WHO to distribute to
affected countries has been critical; with-
out this generosity, patients would have no
access to life-saving drugs, however unsat-
isfactory, when national health budgets are
so stretched.
The tsetse fly, like the trypanosome, also
fascinates scientists but we should be aware
that tsetse can be eliminated or their
populations dramatically reduced by the
simplest of technologies. Sleeping sickness
was eliminated from the island of Principe
in the early years of the 19
th century by use
of sticky backpacks that trapped tsetse.
Morris reduced the incidence of sleeping
sickness in northern Ghana during the
second World War by simply removing
tsetse habitat [5]. In the 1970s–1980s,
scientists in West [11] and southern Africa
[12] provided the basis for effective tsetse
control using odour baits and impregnated
tsetse targets and traps. As there is no
record of insecticide resistance evolving in
tsetse populations, the use of synthetic
pyrethroids poses no risk in terms of the
need for alternative insecticides. While
traps/targets were effective as part of
government funded control schemes, they
have been shown to suffer from sustain-
ability problems when left to affected
communities to handle, related to the
‘tragedy of the commons’ issues. These
common goods problems have been shown
to be surmountable by the treatment of
cattle with insecticide; costs are dramati-
cally reduced when the area of the animal
that is treated with insecticide is restricted,
encouraging uptake by individual poor
cattle keepers [13]. A public–private part-
nership (Stamp Out Sleeping Sickness,
http://www.stampoutsleepingsickness.com/)
set up to prevent the overlap of Gambian and
Rhodesian (acute) forms of sleeping sickness
in Uganda [14] has shown that restricted
application of insecticide provides benefits
not only by removing the main animal
reservoir of Rhodesian sleeping sickness but
also for animal health. Given that the
distribution of sleeping sickness is limited to
ancient and recognised foci, such privately
funded and locally adopted approaches have
more relevance to control of this disease than
the continent-wide approach to eliminate
tsetse from Africa [15].
Control of Gambian sleeping sickness
depends on the strength of national health
systems to provide routine surveillance,
effective diagnosis, and drug availability.
The classic and successful targeted ap-
proach of the dedicated mobile team,
however effective in the past, is no longer
seen as a priority when services need to be
integrated and polyvalent. If the mobile
team is no longer a priority, sleeping
sickness will continue to be a lingering
problemsmoulderinginthe leastaccessible,
poverty-stricken populations and classically
in fragile and post-conflict states [16].
Whilst the optimism of some in the
sleeping sickness community applauding
the nifurtimox/eflornithine announce-
ment is understandable, it is worth re-
membering that a recommendation is one
thing while implementation at scale, by
health services prepared to finance it, is
another. Even if the perfect silver bullet
emerged and was financed, populations
that live far from any functioning health
facility are those in real need. For the
coming decade, only the tried and tested
vertical approaches will work if a sustain-
able impact on Gambian sleeping sick-
ness—a reduction in incidence—is to be
achieved. Research cannot deliver in less
than that time scale, and we know the
classical approaches—early diagnosis by
regular surveillance and treatment—actu-
ally work. Although WHO has defined
sleeping sickness as a ‘‘tool deficient
disease,’’ it can be argued that although
the tools available are not ideal, tools of
proven efficacy do exist. Now is the time to
deploy them at scale.
African trypanosomiasis represents a
failure of both science and public health
[5]. Two failures of responsibility by these
diverse and highly divergent communities
is not an enviable legacy when previous
generations of committed field workers
actually reduced the public health prob-
lem to one of almost zero incidence. We
hope this provides a context and wake-up
call to those who fund research and have
an interest in actually making a difference
to the thousands suffering and dying from
sleeping sickness. Research on the try-
panosome is not the same as research on
sleeping sickness - the two frequently never
meet. Trypanosomes may be attractive
biological models for the researcher, but
these beautiful creatures offer only a grim
reality to those afflicted by an inevitably
fatal disease. Today we are able to
undertake the most elaborate scientific
experimentation on tsetse and trypano-
somes, yet we are barely able to manage
sleeping sickness during the comfort af-
forded by the present inter-epidemic
period. The huge rise in philanthro-
capitalist investments that has been wel-
come in the past decade now needs to
translate into practical solutions for rural
peoples to manage this devastating disease
[17]. Investments that we have seen in
genetics and genomics may reap rewards
in years to come, but in the meantime,
funds must be provided to sustain effective,
if unsexy, control strategies. When the
next epidemic comes, and it will in the
absence of active surveillance and screen-
ing, the tacit knowledge will have been lost
and we will have to start all over again. It
is time that this reality is moved to the
forefront and that we all wake up; we have
been caught sleeping. The international
health community is regularly challenged
to deploy ‘‘lessons learnt’’ through many
bitter experiences. We feel empowered as
both elder practitioners and students of
both tsetse and trypanosomes, with a
degree of field experience, to recall the
famous words of Pete Seeger so pertinent
to sleeping sickness, ‘‘when will they ever
learn, when will they ever learn?’’. Let us
abandon the notion that trypanosome and
tsetse research is synonymous with a case
of sleeping sickness or a health system
trying to control it.
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